At Home Group Inc. (HOME) Reaches $28.94 After 5.00% Up Move; Cellectis SA Ads (CLLS) Shorts Up By 62.49%

December 7, 2017 - By Michael Collier

Cellectis SA Ads (NASDAQ:CLLS) had an increase of 62.49% in short interest. CLLS’s SI was 837,300 shares in December as released by FINRA. Its up 62.49% from 515,300 shares previously. With 236,700 avg volume, 4 days are for Cellectis SA Ads (NASDAQ:CLLS)’s short sellers to cover CLLS’s short positions. The SI to Cellectis SA Ads’s float is 3.46%. The stock increased 1.83% or $0.44 during the last trading session, reaching $24.47. About 21,673 shares traded. Cellectis S.A. (NASDAQ:CLLS) has declined 17.09% since December 7, 2016 and is downtrending. It has underperformed by 33.79% the S&P500.

The stock of At Home Group Inc. (NYSE:HOME) is a huge mover today! The stock increased 17.17% or $4.24 during the last trading session, reaching $28.94. About 2.12M shares traded or 653.99% up from the average. At Home Group Inc. (NYSE:HOME) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months positive chart setup for the $1.75B company. It was reported on Dec, 7 by Barchart.com. We have $30.39 PT which if reached, will make NYSE:HOME worth $87.45 million more.

At Home Group Inc. operates home decor superstores in the United States. The company has market cap of $1.75 billion. The company’s stores offer approximately 50,000 items, such as accent furniture, frames, pottery, bar stools, garden décor, rugs and mats, bedding and bath products, Halloween decorations, sculptures, beds and mattresses, harvest decorations, silk flowers, candles, home organization products, sofas, chairs, kitchenware, stands, Christmas decorations, lamps, storage products, consumables, mirrors, tables, Easter decorations, patio products, vases, floor plants and trees, pet items, wall arts, food preparation items, pillows and cushions, and window treatments. It has a 48.07 P/E ratio. As of September 13, 2017, it operated 141 stores in 33 states.

Among 6 analysts covering At Home Group Inc (NYSE:HOME), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. At Home Group Inc had 12 analyst reports since March 30, 2017 according to SRatingsIntel. The rating was maintained by Jefferies on Thursday, March 30 with “Buy”. SunTrust maintained it with “Buy” rating and $30.0 target in Monday, October 16 report. The rating was maintained by Jefferies with “Buy” on Tuesday, September 5. Suntrust Robinson initiated At Home Group Inc. (NYSE:HOME) on Thursday, July 6 with “Buy” rating. The company was downgraded on Friday, July 14 by Goldman Sachs. Jefferies maintained the shares of HOME in report on Wednesday, August 23 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Wednesday, June 14. The firm has “Buy” rating by KeyBanc Capital Markets given on Tuesday, September 5. The stock has “Buy” rating by Jefferies on Wednesday, June 7. On Thursday, March 30 the stock rating was maintained by Guggenheim with “Buy”.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $886.79 million. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

Among 7 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Cellectis had 13 analyst reports since April 5, 2016 according to SRatingsIntel. The stock of Cellectis S.A. (NASDAQ:CLLS) earned “Buy” rating by Ladenburg Thalmann on Tuesday, April 5. Wells Fargo initiated the stock with “Outperform” rating in Tuesday, February 28 report. The company was maintained on Monday, September 25 by Jefferies. The firm earned “Hold” rating on Friday, October 6 by SunTrust. Nomura maintained the shares of CLLS in report on Wednesday, September 6 with “Buy” rating. On Friday, October 27 the stock rating was maintained by Jefferies with “Buy”. The stock of Cellectis S.A. (NASDAQ:CLLS) has “Buy” rating given on Friday, June 2 by Oppenheimer. Oppenheimer maintained Cellectis S.A. (NASDAQ:CLLS) rating on Wednesday, August 16. Oppenheimer has “Buy” rating and $40.0 target. The firm has “Sell” rating given on Monday, October 2 by Morgan Stanley. The stock of Cellectis S.A. (NASDAQ:CLLS) has “Buy” rating given on Tuesday, June 6 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: